A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.

Phase 2

Pfizer